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Background: PUMA (p53-up-regulated modulator of apoptosis), an apoptosis regulated gene, increased during
endoplasmic reticulum stress. However, the expression of PUMA in cardiomyocytes under mechanical stress is little
known. We aimed to investigate the regulation mechanism of PUMA expression and apoptosis induced by
mechanical stress in cardiomyocytes.
Methods: Aorta-caval (AV) shunt was performed in adult Wistar rats to induce volume overload. Rat neonatal
cardiomyocytes were stretched by vacuum to 20% of maximum elongation at 60 cycles/min.
Results: PUMA protein and mRNA were up-regulated in the shunt group as compared with sham group. The
increased PUMA protein expression and apoptosis induced by shunt was reversed by treatment with atorvastatin at
30 mg/kg/ day orally for 7 days. TUNEL assay showed that treatment with atorvastatin inhibited the apoptosis
induced by volume overload. Cyclic stretch significantly enhanced PUMA protein and gene expression. Addition of
c-jun N-terminal kinase (JNK) inhibitor SP600125, JNK small interfering RNA (siRNA) and interferon-γ (INF-γ) antibody
30 min before stretch reduced the induction of PUMA protein. Gel shift assay demonstrated that stretch increased
the DNA binding activity of interferon regulatory factor-1. Stretch increased, while PUMA-Mut plasmid, SP600125
and INF-γ antibody abolished the PUMA promoter activity induced by stretch. PUMA mediated apoptosis induced
by stretch was reversed by PUMA siRNA and atorvastatin.
Conclusions: Mechanical stress enhanced apoptosis and PUMA expression in cardiomyocytes. Treatment with
atorvastatin reversed both PUMA expression and apoptosis induced by mechanical stress in cardiomyocytes.
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Hypertrophy, a major determinant of morbidity in all
forms of cardiovascular diseases, has become the in-
creasing cardiovascular disorder in the developed coun-
tries [1]. Hypertrophic heart often leads to dilated
cardiomyopathy, and finally leads to congestive heart
failure after sustained overload [2]. Thus, understanding
the molecular mechanisms and developing novel thera-
peutic agents for patients with hypertrophy remains a
major research priority. Cardiac hypertrophy, which
occurs in response to increased mechanical load on the
heart in the form of pressure or volume overload, is* Correspondence: shyukg@ms12.hinet.net
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reproduction in any medium, provided the orcharacterized by increased cell size, enhanced protein
synthesis, and re-expression of fetal genes.
The etiology of heart failure involves multiple agents
and conditions, but the progressive loss of cardiomyo-
cytes is one of the most important pathogenic compo-
nents. Cardiac apoptosis may be an important factor
during the transition from compensatory hypertrophy to
heart failure [3]. The role of cardiomyocytes apoptosis
during heart failure is not completely understood.
Therefore, the possibility of reducing cardiomyocytes
loss by inhibiting apoptosis has potentially important
implications in the treatment of heart failure. To prevent
the progression of hypertrophy and heart failure, it is
important to have a full understanding of the apoptosis
mechanism in cardiomyocytes and thus to identify po-
tential therapeutic targets [4].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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membrane-bound death receptor, release of proapoptotic
factors from mitochondria or stress at the endoplasmic
reticulum (ER). ER is a central organelle entrusted with
lipid synthesis, calcium homeostasis, protein folding,
and maturation [5]. Thus, the development of the ER
in hypertrophic and failing hearts may implicate the
compensatory response to the up-regulated protein
synthesis. Correctly folded proteins exit the ER and
are transported to the Golgi and other destinations
within the cell, but proteins that fail to fold properly
misfolded proteins are retained in the ER and their
accumulation may constitute a form of stress to the
cell called ER stress [6]. In the heart, hypoxia, ische-
mia/reperfusion, hypertrophy, pressure overload, and
drug-induced insults can result in activation of ER
stress [7]. In order to overcome ER stress and main-
tain cell homeostasis, ER stress triggers a specific sig-
naling pathway called unfolded protein response
(UPR). As ER stress is excess and/or prolonged, the
UPR can not reverse the damage and then causes the
cell to undergo apoptosis [8].
One component of the ER stress-mediated apoptosis
pathway is the p53-upregulated modulator of apoptosis
(PUMA), also known as Bcl-2 binding component 3
[9,10]. PUMA is a Bcl-2 homology 3 (BH3)-only Bcl-2
family member and a critical mediator of p53-dependent
and -independent apoptosis under various stimuli in sev-
eral tissues and cells [11,12]. Besides, interferon regula-
tor factor-1 (IRF-1) could bind to the promoter of
PUMA and activate PUMA transcription induced by
interferon-γ [13].
PUMA has been induced by cyclic stretch in VSMCs
[14]. This system has been applied widely in studying
the molecular mechanisms of gene expression and signal
transduction in many cell types [15]. There was a good
evidence to show that PUMA plays an important role in
cardiomyocytes apoptosis upon ER stress and ischemia/
reperfusion [16]. However, there is no conclusive proof
on how mechanical cyclic stretch affects the PUMA on
the apoptosis in cardiomyocytes.
The 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA)
reductase inhibitors, statins, have been associated with
reduced morbidity and mortality in patients with coronary
artery disease [17]. The application of atorvastatin in
patients with non-ischemic heart failure improved left
ventricular ejection fraction and attenuated adverse
left ventricular remodeling [18]. The beneficial effects
of atorvastatin in attenuating cardiac hypertrophy also
extend to acquired forms, such as pressure-overload
induced cardiac hypertrophy and cardiac remodeling
[19]. Recently, Song et al. reported that the possible
mechanism by which atorvastatin functions in pro-
tecting against heart failure through downregulatingER stress response [20]. However, the effect of ator-
vastatin on PUMA-mediated myocardial apoptosis
induced by AV-shunt and cyclic stretch is little
known. Therefore, the purpose of this study was to
test whether PUMA and myocardial apoptosis was
induced by the AV shunt model in rat myocardium.
Besides, we determined the molecular mechanism of
PUMA regulation in cardiomyocytes apoptosis
induced by cyclic stretch. We also used atorvastatin
to inhibit the PUMA expression and apoptosis under
AV shunt and cyclic stretch.
Methods
The aorta-caval shunt (AV shunt) rat model
AV shunt was performed on rats to induce volume over-
load. On the day of surgery, the Wistar rats weighing
280 to 330 g were anesthetized with 2% isoflurane and
the vena cava and aorta were exposed via abdominal
midline incision after confirming a fully anaesthetized
state (e.g. no response to toe pinching). The aorta-caval
shunt was produced as previously described [14]. The
rats were euthanized with an overdose of isoflurane. All
study protocols were approved by our Institutional
Committee of Animal Care and Use (Protocol number
#0990816001) and were carried out in accordance with
the Guide for the Care and Use of Laboratory Animals
(NIH publication No. 86–23, revised 1996).
Cardiomyocytes culture
Cardiomyocytes were obtained from Wistar rats aged 2–
3 days old by trypsinization, as previously described [21].
Cultured cardiomyocytes thus obtained were > 95% pure
as revealed by observation of contractile characteristics
with a light microscope and stained with anti-desmin
antibody (Dako Cytomation, Glostrup, Denmark). Cardi-
omyocytes were seeded on flexible membranes base of
six culture wells at a cell density of 5X105 cells per well
in Ham’s F-10 containing 20% fetal calf serum. After
3 days in culture, cells were transferred to serum-free
medium (Ham’s F-10) and subjected to cyclic stretch.
In vitro cyclic stretch on cultured cardiomyocytes
The Flexcell FX-2000 strain unit consists of a vacuum
unit linked to a valve controlled by a computer program.
Cardiomyocytes cultured on the flexible membrane base
were subjected to cyclic stretch produced by this
computer-controlled application of sinusoidal negative
pressure with a peak level ofﬃ 15 kPa at a frequency of
1 Hz (60 cycles per min) for various periods of time. To
determine the roles of c-Jun N-terminal kinase (JNK),
p38 or p44 mitogen-activated protein (MAP) kinase in
the expression of stretch-induced PUMA expression,
cardiomyocytes were pretreated with SP600125 (a po-
tent, cell permeable, selective, and reversible inhibitor of
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highly specific, cell permeable inhibitor of p38 kinase,
3 μM, Calbiochem), PD98059 (a specific and potent in-
hibitor of ERK kinase, 50 μM, Calbiochem) or N-
acetylcysteine (a free radical scavenger, 500 μM) for
30 min, respectively, followed by cyclic stretch.
Western blot analysis
A Western blot was performed as previously described
[14]. Goat monoclonal anti-PUMA antibody (1: 200;
Santa Cruz Biotechnology, Santa Cruz) was used. Equal
protein loading of the samples was verified by incubating
with the monoclonal antibody α-tubulin.
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was performed as previously described [14].
The primers used were as follows: PUMA, 5’-d(CCCTG
GAGGGTCCTGTACAA)-3’ (forward) and 5’-d(CTCTG
TGGCCCCTGGGTAA)-3’ (reverse); and GAPDH, 5’-d
(CATCACCATCTTCCAGGAGC) (forward) and 5’-d
(GGATGATGTTCTGGGCTGCC)-3’ (reverse).
Electrophoretic mobility shift assay (EMSA)
Nuclear protein concentrations from cultured cardio-
myocytes were determined by Biorad protein assay.
Consensus and control oligonucleotides (Santa Cruz
Biotechnology) were labeled by polynucleotides kinase
incorporation of [γ32-P]ATP. After the IRF-1 was radio-
labeled, the nuclear extracts (4 μg of protein in 2 μl of
nuclear extract) were mixed with 20 pmol of the appro-
priate [γ32-P]ATP-labeled consensus or mutant oligo-
nucleotide in a total volume 20 μl for 30 min at room
temperature. The samples were then resolved on a 4%
polyacrylamide gel. Gels were dried and imaged by auto-
radiography. Controls were performed in each case with
mutant or cold oligonucleotides to compete with labeled
sequence.
RNA interference
Cardiomyocytes were transfected with 800 ng siRNA of
PUMA or JNK (Dharmacon, Lafayette, Colorado, USA).
PUMA or JNK siRNA are target-specific 21 nt siRNAs
according to a computer program provided by Dharma-
con. The PUMA and JNK targeted base sequences were,
as follows: sense: 5’-AAGAAGAGCAACAUCGACA and
5’-CGUGGAUUUAUGGUCUGUGdTdT-3’, respectively;
and antisense: 5’-P. ACAAGAAGAGCAACAUCGA and
5’-CACAGACCAUAAAUCCACCdTdT-3, respectively.
Green fluorescent protein (GFP) siRNA was used as a
negative control, with the following: sense: 5’-P.GGC
UACGUCCAGGAGCGCACC-3’ and antisense: 5’-P.
UGCGCUCCUG GACGUAGCCUU-3’ (Dharmacon).
After overnight incubation, cells were stretched andsubjected to analysis by Western blot, EMSA, immuno-
histochemistry and detection of apoptosis.
Promoter activity assay
A human PUMA promoter construct was generated as
previously described (human PUMA: -2183 to −1490,
containing an IRF-1 binding site [13]). The plasmids
were transfected into cardiomyocytes using a low
pressure-accelerated gene gun (Bioware Technologies,
Taipei, Taiwan) essentially following the protocol from
the manufacturer. Test plasmid (2 μg) and control
plasmid (pGL4-Renilla luciferase; 0.02 μg) were co-
transfected with a gene gun in each well, and then
replaced with normal cultured medium. Following 6
hours of cyclic stretch, cell extracts were prepared for
the Dual-Luciferase Reporter Assay System (Promega
Corp., Madison, Wisconsin, USA) and measured for dual
luciferase activity by luminometer (Turner Designs Inc.,
Sunnyvale, California, USA).
Measurement of interferon-γ concentrations
Conditioned medium from cardiomyocytes subjected to
cyclic stretch and those from control (unstretched) cells
were collected for IFN-γ measurement. IFN-γ levels
were measured using a quantitative sandwich enzyme
immunoassay technique (R & D Systems, Minneapolis,
MN, USA).
Flow cytometric analysis for apoptotic quantification
Cardiomyocytes were fixed with 70% ethanol and treated
with RNase. Then nuclei were stained with propidium
iodide (Molecular Probes, Eugene, Oregon) and FITC
Annexin V. DNA content was measured using by a
FACS Calibur flow cytometer and Cell Quest software
(Becton Dickinson, Franklin Lakes, NJ, USA). Ten thou-
sand cells were counted in all assays. Apoptotic cells
were quantified as the percentage of cells stained with
Annexin V.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) assay
DNA fragmentation was determined by TUNEL using
the ApopTag peroxidase in situ apoptosis detection kit
(Chemicon International, Temecula, CA, USA). TUNEL
assay was performed as previously described [14]. Fluor-
escence signals were obtained with a confocal microscope
(Nikon D-ECLIPSE) and assayed using its associated image
processing and analysis software.
Statistical analysis
All results were expressed as mean + S.E.M. Statistical
significance was evaluated using analysis of variance
(ANOVA; GraphPad Software Inc., San Diego, CA,
USA). The Dunnett’s test was used to compare multiple
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comparison was used for pairwise comparisons between
multiple groups following the ANOVA. A p < 0.05 was
considered as significant.
Results
AV shunt enhances the expression of myocardial PUMA
protein and mRNA expression
As shown in Figure 1, the PUMA protein expression in
































































Figure 1 Effect of in vivo model of aorta-caval shunt (AV shunt) on m
PUMA in rat myocardium after short-term induction of AV shunt. (B) Quant
normalized to α-tubulin measurement and then expressed as a ratio of nor
vs. control. +P < 0.01 vs. control. (C) Fold increases in PUMA mRNA as a resu
been normalized to match GADPH measurement and then expressed as a
group. (n = 5 per group).shunt for 7 days. Real-time PCR also showed that
PUMA mRNA was up-regulated after AV shunt. These
findings indicate that PUMA is induced by volume over-
load in rat myocardium.
Atorvastatin reduces myocardial PUMA protein
expression induced by AV shunt
The PUMA protein increased 3.6-fold at 7 days of AV
shunt when compared with the sham group (Figure 2).
Since most oral dose of statins used in animal study5 7 10 day
AV shunt
5 7 10 day
*
**




yocardial PUMA protein levels. (A) Representative Western blots for
itative analysis of PUMA protein levels. The values have been
malized values to PUMA protein in sham. (n = 5 per group). *P < 0.05
lt of induction of AV shunt. The values from experiment groups have









































Figure 2 Effects of atorvastatin on rat myocardium PUMA protein expression induced by AV shunt. (A) Representative Western blots for
PUMA after induction of AV shunt with or without treatment with atorvastatin. (B) Quantitative analysis of PUMA protein levels. The values from
myocardium after AV shunt have been normalized to matched α-tubulin measurement and then expressed as a ratio of normalized values to
protein in control group (n = 3 per group). *P < 0.01 vs. control.
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in the present study. Treatment with atorvastatin at
30 mg/kg/ day orally for 7 days significantly blocked the
increase of PUMA protein induced by AV shunt. How-
ever, treatment with atorvastatin in the sham group did
not affect the protein expression of PUMA. These find-
ings revealed that PUMA protein expression induced by
AV shunt was reduced by atorvastatin. AV shunt for
10 days may induce congestive heart failure in rats and
therefore the PUMA expression is changed as compared
with 7 days.
Atorvastatin inhibits apoptosis induced by AV shunt
As shown in Figure 3, AV shunt significantly increased
apoptotic nuclei. Treatment with atorvastatin signifi-
cantly reduced TUNEL positive nuclei. This result indi-
cates that atorvastatin inhibits myocardial apoptosis
induced by AV shunt.
Cyclic stretch enhances PUMA protein and mRNA
expression in cardiomyocytes
The level of PUMA protein began to increase as early as
6 h after stretch to 20% elongation was applied, reacheda maximum of 2.2-fold over the control by 14 h and
remained elevated up to 18 h. When cardiomyocytes
were stretched at 10% elongation, the level of PUMA
protein was similar to that of control without stretch
(Figure 4A 4B). The real-time PCR showed that PUMA
mRNA increased significantly after 14 h of stretch at
20% elongation (Figure 4C). These results revealed that
PUMA expression in cardiomyocytes was induced by
stretch. The effect of PUMA expression was maximal at
18 hours after stretch but not at 24 hours, indicating the
transient effect of mechanical stretch on PUMA expres-
sion in cardiac myocytes.
Stretch-induced PUMA protein expression in
cardiomyocytes is mediated by JNK and IFN-γ
Cardiomyocytes were stretched by 20% for 18 h in the
presence and absence of various inhibitors or siRNA to
determine the signaling pathway mediating the stretch-
induced increases in PUMA expression in cardio-
myocytes. As shown in Figure 5, the stretch-induced
increases of PUMA proteins were significantly blocked
after the addition of SP600125 30 min before stretch.
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Figure 3 AV shunt enhances rat myocardial apoptosis. (A) Representative microscopy images of rat myocardium after AV shunt, treatment of
atorvastatin before AV shunt then stained with a TUNEL kit. Arrow means TUNEL positive cells. Similar results were observed in another two
independent experiments. (B) Quantitative analysis of TUNEL positive cells (%).*P < 0.01 vs. control.
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the addition of SB203580. Moreover, JNK siRNA also
completely blocked the PUMA expression induced by
cyclic stretch. Furthermore, conditioned medium alone
also had a similar effect on PUMA expression levels as cyc-
lic stretch, whereas DMSO alone, as a vehicle control, and
control siRNA did not affect PUMA expression levels
following cyclic stretch. Addition of IFN-γ monoclonalantibody 30 min before stretch also significantly blocked
the expression of PUMA induced by cyclic stretch. These
results indicate that PUMA protein expression induced by
stretch in cardiomyocytes is mediated by JNK and IFN-γ.
Cyclic stretch enhances IRF-1 binding activity
Cyclic stretch significantly began to increase the DNA-



































































Figure 4 Effects of cyclic stretch on PUMA expression in cardiomyocytes. (A) Representative Western blots for PUMA in cardiomyocytes
subjected to cyclic stretch by 20 or 10 % for various periods of time. (B) Quantitative analysis of PUMA protein levels. The values from stretched
cardiomyocytes have been normalized to matched α-tubulin measurement and then expressed as a ratio of normalized values to protein in
control group (n = 4 per group). *P < 0.01 vs. control. (C) Quantitative analysis of PUMA mRNA levels. The values from stretched cardiomyocytes
have been normalized to matched GAPDH measurement and then expressed as a ratio of normalized values to mRNA in control group (n = 5 per
group). *P < 0.01 vs. control.
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remained elevated for 24 h (Figure 6A). An excess of un-
labeled IRF-1 oligonucleotide competed with the probe
for binding IRF-1 protein, whereas an oligonucleotide
containing a 2-bp substitution in the IRF-1 binding site
did not compete for binding. Addition of SP600125, JNK
siRNA and IFN-γ antibody (5 mg/mL, purchased from
R&D Systems) 30 min prior to stretch abolished the
DNA-protein binding activity induced by cyclic stretch.Moreover, exogenous IFN-γ also induced IRF-1 binding
activity. These results demonstrated that stretch
enhanced IRF-1 binding activity was mediated by IFN-γ
and JNK in cardiomyocytes.
Cyclic stretch increases PUMA promoter activity through
IRF-1 in cardiomyocytes
The PUMA promoter construct contains CREB, NFAT,
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Figure 5 Effects of MAP kinase inhibitors on PUMA protein expression induced by cyclic stretch in cardiomyocytes. (A) Representative
Western blots for PUMA protein levels in cardiomyocytes subjected to cyclic stretch in the absence or presence of MAP kinase inhibitors, IFN-γ
Ab, siRNA and vehicle (DMSO 0.1 %). CM= conditioned medium. (B) Quantitative analysis of PUMA protein levels. The values from stretched
cardiomyocytes have been normalized to matched α-tubulin measurement and then expressed as a ratio of normalized values to protein in
control group (n = 4 per group). *P < 0.01 vs. control.
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IRF-1 promoter. This result indicates that PUMA ex-
pression is induced at transcriptional level during stretch
in cardiomyocytes. Besides, transient transfection of
PUMA-Mut plasmid and addition of SP600125 and IFN-
γ Ab abolished the promoter activity induced by stretch.
Atorvastatin reduces PUMA expression and apoptosis
induced by cyclic stretch in cardiomyocytes
As shown in Additional file 1: Figure S1, atorvastatin
significantly reduced PUMA protein expression induced
by stretch. As PUMA is an apoptosis related gene and
enhanced by volume overload, we speculated that
PUMA is involved in apoptosis during cyclic stretch. As
shown in Figure 7A, apoptosis was assessed by PI/
annexin V double staining and FACS analysis. The per-
centage of cells stained with annexin V was elevated fol-
lowing stretch for 18 h and the addition of IFN-γ. These
increases of annexin V positive cells induced by stretch
were significantly reversed by PUMA siRNA and 10 μM
atorvastatin. Besides, a significant increase in TUNEL-positive nuclei was present after stretch for 18 h and the
addition of IFN-γ (Figure 7B). These increases in
TUNEL-positive nuclei of cardiomyocytes induced by
stretch were significantly reversed by PUMA siRNA and
atorvastatin. These findings demonstrate that PUMA
mediates stretch-induced apoptosis of cardiomyocytes is
inhibited by atorvastatin.
Cyclic stretch stimulates the secretion of IFN-γ from
cultured cardiomyocytes
As shown in Additional file 1: Figure S2, cyclic stretch
significantly increased the IFN-γ secretion from cultured
cardiomyocytes at 2 h, and it remained elevated for 24 h.
This result indicates that stretch stimulates the secretion
of IFN-γ from cultured cardiomyocytes.
Discussion
In the present study, we demonstrated that (1) in vivo
acute hemodynamic overload enhances rat myocardium
PUMA expression, (2) atorvastatin inhibits myocardial
PUMA expression and apoptosis induced by AV shunt,
Figure 6 Effects of cyclic stretch on PUMA binding and promoter activity in cardiomyocytes. (A) Representative EMSA showing protein
binding to IRF-1 oligonucleotide in nuclear extracts of cardiomyocytes following cyclic stretch during various times and in the absence or
presence of JNK inhibitors or siRNA, IFN-γ antibody or addition of 200 pg/ml IFN-γ. Arrows indicate the mobility of the complex. Similar results
were found in another two independent experiments. Cold oligo means unlabeled IRF-1 oligonucleotide. (B) Constructs of PUMA promoter gene.
(C) Quantitative analysis of PUMA promoter activity. Cardiomyocytes were transiently transfected with pPUMA-Luc by a gene gun. The luciferase
activity in cell lysates was measured and was normalized with Renilla activity (n = 3 per group). *P < 0.01 vs. control.
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cardiomyocytes, (4) JNK MAP kinase and the IRF-1
transcription factor are involved in the signaling pathway
of PUMA induced by stretch in cardiomyocytes, (5)
IFN-γ mediates the increase in PUMA expression
induced by cyclic stretch, (6) cyclic stretch induces car-
diomyocytes apoptosis via PUMA, (7) cardiomyocytes
apoptosis induced by cyclic stretch is inhibited by
atorvastatin.
We demonstrated that myocardium PUMA protein
and mRNA expression were up-regulated in a model of
AV shunt in myocardium. We have previously demon-
strated that aortic PUMA expression was induced by
both pressure and volume overload [14]. In this study,we presented that PUMA expression was induced by
cyclic stretch in cardiomyocytes. Cyclic stretch of cardio-
myocytes increased both the expression of PUMA pro-
tein and mRNA. PUMA protein expression was up-
regulated in both a time- and load- dependent manner
by cyclic stretch. It has been demonstrated that PUMA
expression is induced under various stress in cancer,
neuronal and cardiovascular cells [12]. Besides, Li et al.
also reported that hypoxia/reoxygenation could upregu-
late the expression of PUMA in cardiomyocytes [22].
Nickson et al. have shown that ER-stress induced by
thapsigargin or tunicamycin leads to transcriptional
upregulation of PUMA in rat neonatal cardiac myocytes
[16]. In the present study, we performed in vivo model
Annexin V-FITC
Control Stretch 18 h
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+ PUMA siRNA
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Figure 7 (See legend on next page.)
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Figure 7 Effect of PUMA on stretch-induced apoptosis in cardiomyocytes. (A) Cardiomyocytes were subjected to cyclic stretch for 18 h,
addition of 10 μM atorvastatin, siRNA before stretch or addition of 200 pg/ml IFN-γ alone. Quantification of the apoptotic fractions was
performed using FACScan. Cells that stain negative for both Annexin V and PI are alive. Cells that stain positive for Annexin V and negative for PI
are undergoing apoptosis. Cells that stain positive for both Annexin V and PI are in the end stage of apoptosis called second apoptosis. (n = 3).
*P < 0.05 vs. control. **P < 0.05 vs. stretch 18 h. (B) Representative microscopy images of cardiomyocytes after cyclic stretch for 18 h, addition of
atorvastatin, siRNA before stretch or addition of IFN-γ, then stained with a TUNEL kit. Similar results were observed in another two independent
experiments. Arrow indicates TUNEL positive cells.
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experiment with neonatal cardiomyocytes. AV shunt
model is difficult to perform in neonatal rats. The mech-
anism of stretch-induced apoptosis in neonatal cardio-
myocytes may not apply to the findings in the in vivo
AV shunt model in adult animal.
Our findings indicated that myocardium apoptosis was
up-regulated in a model of volume overload. It has been
suggested that BAX is upregulated and may play a role
in cardiomyocyte apoptosis in heart failure due to vol-
ume overload [23]. Besides, Dent et al. also reported that
upregulation of BAX may play a major role in cardio-
myocyte apoptosis in heart failure due to volume over-
load in male rats [24]. According to these studies, we
may suggest that volume overload enhance apoptosis of
cardiomyocytes. Besides, we also found that atorvastatin
inhibited PUMA expression and apoptosis induced by
AV-shunt. Functional inhibition of PUMA has been indi-
cated a new potential therapeutic target for inhibiting
the progression of hypertrophy to heart failure [25]. Pre-
vious study has reported that atorvastatin significantly
improves cardiac function after myocardial infarction
due to a decrease in myocardial apoptosis [17]. Besides,
it has been shown that treatment with atorvastatin reversed
established cardiac hypertrophy and interstitial fibrosis and
improved cardiac function [26]. Wu et al. also suggested
that the administration of valsartan can ameliorate the ER
stress through blocking the CHOP/PUMA-mediated myo-
cardial apoptosis in streptozotocin-induced diabetic rats
[27]. Moreover, deletion of PUMA appears to protect
hematopoietic stem cells during ionizing radiation for ma-
lignancy [28]. Accordingly, we may suggest that PUMA in-
hibitor could be a potential candidate to improve the
myocardial apoptosis and heart failure.
We found that cyclic stretch enhanced IFN-γ expres-
sion in cardiomyocytes (Additional file 1: Figure S2 ).
Our results also suggested that IFN-γ is responsible for
IRF-1-DNA binding in cardiomyocytes. We further
demonstrated that the JNK1 inhibitor and siRNA signifi-
cantly inhibited PUMA expression induced by stretch.
These results indicated that the JNK MAP kinase path-
way is the major pathway involved in the induction of
PUMA by stretch and mediates the increased binding
activity of IRF-1 in cardiomyocytes. Zhao et al. suggested
that the JNK-potentiated Akt-FoxO3a and JNK-mediatedc-Jun pathways cooperatively trigger PUMA expression
in ovarian cancer cells [29]. Besides, our reporter gene
assay found that increased transcriptional activity of
PUMA promoter by stretch was IRF-1 dependent. In
general, PUMA is transactivated by p53 under various
stresses, like DNA damage, hypoxia and ER stress. How-
ever, PUMA is also activated by IRF-1 to begin p53-
independent apoptotic responses to nongenotoxic stim-
uli, including growth factor/cytokine deprivation, ische-
mia/reperfusion and ER stress [13]. Otherwise, CHOP
could also transcriptional regulates PUMA expression.
Kumar et al. reported that IRF-1 may be involved in the
pathological response of human fetal myocyte to septic
serum from patients. Besides, their study also indicated
that c-Jun NH2-terminal kinase may play an important
role in the induction of fetal myocyte apoptosis by
addition of human septic serum [30]. It has also been
demonstrated that p53 activation plays a crucial role in
PUMA-mediated ROS generation induced by silibinin in
A431 cells [31]. In this study, our finding indicated that
JNK and IRF-1 may involve in the PUMA expression
induced by stretch in cardiomyocytes. Furthermore, we
found that an exogenous addition of IFN-γ to non-
stretched cardiomyocytes was sufficient to induce cardi-
omyocytes apoptosis. Chae et al. also reported that treat-
ment of neonatal rat ventricular cardiomyocytes with
IFN-γ induces apoptosis via an NO-dependent pathway
[32]. However, it has been indicated that incubation of
cardiomyocytes with TNF-α, but not with IFN-γ, caused
significant caspase-3 activation and apoptosis [33]. Li
et al. [33] used adult mice cardiomyocytes, whereas Chae
et al. [32] and our studies used neonatal rat cardiomyo-
cytes. Different species may explain the discrepancy.
In this study, we demonstrated that cardiomyocytes
apoptosis induced by stretch is mediated by PUMA. It
has been demonstrated that cyclic stretch could induce
cardiovascular cells apoptosis [34]. Previously, our group
has also demonstrated cyclic stretch could induce car-
diovascular cells apoptosis [21]. Recent studies showed
that ER stress response could also cause cardiomyocytes
apoptosis during the progression of heart failure [35]. Li
et al. also revealed that PUMA participates in hypoxia/reox-
ygenation-triggered cardiomyocyte apoptosis by interfering
with mitochondrial pathway [36]. PUMA has been reported
as an essential mediator of cardiomyocyte death upon
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http://www.jbiomedsci.com/content/19/1/72ischemia/reperfusion injury [12]. These observations are
consistent with our data regarding PUMA-mediated car-
diomyocytes apoptosis. Besides, PUMA also plays an im-
portant role on apoptosis in other cells. Antony et al.
implicate that Bim-independent apoptosis by BITC in can-
cer cells is mediated by PUMA [37]. It has also been
reported that in CCHFV-infected hepatocytes the over-
expression of PUMA, Noxa and CHOP may involve in the
crosstalk between the ER-stress and mitochondrial apop-
tosis [38].Conclusions
In summary, our result reveals that atorvastatin inhibits
myocardium PUMA expression and apoptosis induced
by AV shunt. Cyclic stretch enhances PUMA expression
in cardiomyocytes. The stretch-induced PUMA is
mediated by IFN-γ, JNK MAP kinase and IRF-1 pathway.
We also demonstrate that atorvastatin reduces the
PUMA-mediated apoptosis induced by stretch. Further
studies can help to identify the mechanism through
which PUMA mediates apoptosis and to clarify the spe-
cific role of PUMA in heart failure.Additional file
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Representative Western blots for PUMA protein levels in cardiomyocytes
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S2: Cyclic stretch increases release of rat IFN-γ from cardiomyocytes
subjected to cyclic stretch by 20% for various periods of time (n = 3 per
group). *P < 0.01 vs. control.Abbreviations
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